Scarica l'app Stockscreener
46.96
0.70%
-0.33
Dopo l'orario di chiusura:
46.01
-0.95
-2.02%
Precedente Chiudi:
$47.29
Aprire:
$46.22
Volume 24 ore:
464.32K
Relative Volume:
0.54
Capitalizzazione di mercato:
$3.10B
Reddito:
$58.89M
Utile/perdita netta:
$-240.88M
Rapporto P/E:
-15.15
EPS:
-3.1
Flusso di cassa netto:
$-239.96M
1 W Prestazione:
-1.39%
1M Prestazione:
+50.80%
6M Prestazione:
+11.46%
1 anno Prestazione:
+34.67%
Intervallo 1D:
$46.04
$47.33
Intervallo di 1 settimana:
$45.80
$50.27
Portata 52W:
$19.45
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Nome
Kymera Therapeutics Inc
Settore
Industria
Telefono
857-285-5314
Indirizzo
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Confronta KYMR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
46.96 | 3.10B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-03 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-20 | Ripresa | Stifel | Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Market Perform |
| 2024-12-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-26 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Iniziato | Oppenheimer | Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Iniziato | Truist | Buy |
| 2023-05-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Iniziato | Raymond James | Mkt Perform |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-08-03 | Iniziato | Goldman | Buy |
| 2022-07-20 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | JP Morgan | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2021-09-30 | Iniziato | B. Riley Securities | Neutral |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-09-15 | Iniziato | BofA Securities | Neutral |
| 2020-09-15 | Iniziato | Cowen | Outperform |
| 2020-09-15 | Iniziato | Guggenheim | Buy |
| 2020-09-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
Kymera draws upgrades after early-stage data for anti-inflammatory agent - MSN
Kymera Therapeutics soars 35% on positive phase 1 results for oral STAT6 degrader KT-621 - MSN
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - Investing.com
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - MarketBeat
Morgan Stanley Maintains Hold Rating on Kymera Therapeutics (KYMR), Keeps PT - MSN
Kymera jumps 16% as it prepares to release phase 1 data on inflammatory diseases asset - MSN
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio? - Benzinga
B. Riley Research Analysts Lower Earnings Estimates for KYMR - Defense World
Top 10 NASDAQ Stocks with Strong Growth Potential by Kalkine - Kalkine Media
Ameriprise Financial Inc. Takes Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Q2 EPS Forecast for Kymera Therapeutics Boosted by Analyst - Defense World
Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial - Barron's
Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating - MSN
BofA Upgrades Kymera Therapeutics (KYMR) to Buy, Lifts PT to $51 - MSN
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Clinical Trial of KT-621 - MSN
Kymera Therapeutics, Inc.’s (KYMR) Upgraded to Buy Following Positive Phase 1 Results for Oral STAT6 Degrader - MSN
JPMorgan Chase & Co. Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Upgraded to “Overweight” at Morgan Stanley - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Sees Large Volume Increase on Analyst Upgrade - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Upgraded by B. Riley to “Buy” Rating - Defense World
B. Riley Securities Upgrades Kymera Therapeutics (KYMR) - Nasdaq
Kymera Therapeutics Executives and Directors Sell Shares - TradingView
Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race - insights.citeline.com
Kymera stock draws upgrades after trial data (KYMR:NASDAQ) - Seeking Alpha
Morgan Stanley upgrades Kymera stock rating, raises price target By Investing.com - Investing.com Canada
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug - TradingView
Kymera STAT6 Degrader Phase 1 Data a 'Key De-Risking Event,' Morgan Stanley Says - marketscreener.com
Kymera Therapeutics (KYMR) Receives Analyst Upgrade and Price Ta - GuruFocus
Kymera Therapeutics (KYMR) Receives Analyst Upgrade and Price Target Boost | KYMR Stock News - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Upgraded to “Buy” at Bank of America - Defense World
Kymera Therapeutics (KYMR) Sees Price Target Raised by JP Morgan - GuruFocus
What 6 Analyst Ratings Have To Say About Kymera Therapeutics - Nasdaq
Stifel Adjusts Price Target on Kymera Therapeutics to $68 From $55, Maintains Buy Rating - marketscreener.com
Kymera Therapeutics (KYMR) Sees Price Target Raised by JP Morgan | KYMR Stock News - GuruFocus
Kymera Therapeutics (KYMR) Receives Upgraded Target Price and Po - GuruFocus
JPMorgan Raises Kymera Therapeutics (KYMR) Target Price Amid Positive Phase 1 Data | KYMR Stock News - GuruFocus
Morgan Stanley Upgrades Kymera Therapeutics to Overweight From Equalweight, Raises Price Target to $79 From $49 - marketscreener.com
Kymera Therapeutics (KYMR) Shares Boosted by Positive KT-621 Dat - GuruFocus
Wells Fargo reiterates overweight rating on Kymera Therapeutics stock By Investing.com - Investing.com UK
Where are the Opportunities in (KYMR) - news.stocktradersdaily.com
Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday - MSN
Kymera reports promising Phase 1 results for KT-621 By Investing.com - Investing.com South Africa
Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025 - MSN
These 10 Stocks Blew Past Expectations - Insider Monkey
Kymera’s STAT6 Degrader for Inflammatory Disease Shows Early Success in Phase I - Genetic Engineering and Biotechnology News
Kymera Therapeutics (KYMR) Gains Favor with Morgan Stanley Upgra - GuruFocus
Kymera Therapeutics (KYMR) Gains Favor with Morgan Stanley Upgrade | KYMR Stock News - GuruFocus
Kymera, with new data, takes early step toward a Dupixent-like pill - BioPharma Dive
TRUIST SECURITIES MAINTAINS BUY RATING ON KYMERA STOCK AFTER POSITIVE STUDY RESULTS - Investing.com UK
Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data (NASDAQ:KYMR) - Seeking Alpha
Citi Increases Price Target for Kymera Therapeutics (KYMR) to $6 - GuruFocus
Kymera Therapeutics Inc Azioni (KYMR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):